Cipla
Rahul Singh is an accomplished professional with extensive experience in respiratory patient care and marketing within the pharmaceutical industry. Currently serving as the Head of Respiratory Patient Care at Cipla since June 2013, Rahul manages the Breathefree initiative and oversees a significant portfolio that includes leading brands like Foracort and Duolin. Previous roles at Cipla include Sr Marketing Head and Group Product Manager, where Rahul demonstrated expertise in demand generation, patient onboarding, and market development. Prior to Cipla, Rahul held positions at Glenmark Pharmaceuticals and Themis Medicare Ltd, focusing on diverse therapeutic areas, and began a career in pharmacovigilance at Tata Consultancy Services. Educational credentials include a Bachelor of Pharmacy from the University of Mumbai and an MBA in Marketing from DY Patil University.
This person is not in any teams
Cipla
18 followers
Cipla is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.